Currently, anti–PD-1/PD-L1 checkpoint antibodies are approved by the FDA to treat melanoma, non–small cell lung cancer (NSCLC), Hodgkin lymphoma, Merkel cell carcinoma, renal cell carcinoma (RCC), urothelial carcinoma, and head and neck cancers (Boutros et al., 2016; Topalian et al., 2012). Here, CD274 is linked to non-small cell lung carcinoma.